Last reviewed 2026-06-02 · How we verify

Prospidelong

Research Institute for Physical Chemical Problems of the Belarusian State University · Phase 2 active Small molecule ✓ Verified Jun 2026

Prospidelong is a Small molecule drug developed by Research Institute for Physical Chemical Problems of the Belarusian State University. It is currently in Phase 2 development.

Prospidelong is being studied in a clinical trial for its effectiveness in treating gastric cancer with peritoneal dissemination. The trial is comparing the use of Prospidelong with chemotherapy.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Prospidelong
Sponsor	Research Institute for Physical Chemical Problems of the Belarusian State University
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Prospidelong CI brief — competitive landscape report
Prospidelong updates RSS · CI watch RSS
Research Institute for Physical Chemical Problems of the Belarusian State University portfolio CI

Frequently asked questions about Prospidelong

What is Prospidelong?

Prospidelong is a Small molecule drug developed by Research Institute for Physical Chemical Problems of the Belarusian State University.

Who makes Prospidelong?

Prospidelong is developed by Research Institute for Physical Chemical Problems of the Belarusian State University (see full Research Institute for Physical Chemical Problems of the Belarusian State University pipeline at /company/research-institute-for-physical-chemical-problems-of-the-belarusian-state-univer).

What development phase is Prospidelong in?

Prospidelong is in Phase 2.

Manufacturer: Research Institute for Physical Chemical Problems of the Belarusian State University — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing